0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027
Published Date: February 2021
|
Report Code: QYRE-Auto-0N4529
Home | Category |Health |Health Conditions |Neurological Conditions
Global Transthyretin amyloid cardiomyopathy ATTR CM Treatment Market Size Status and Forecast 2021 2027

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027

Code: QYRE-Auto-0N4529
Report
February 2021
93 Pages
QYResearch
Region: Global, North America, Europe, Canada, UAE, Saudi Arabia, Turkey, Southeast Asia, France, Germany, South Korea, Italy, Russia,
Description
Table of Content
Tables & Figures
Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
    Transthyretin Stabilizers
    Nonsteroidal Anti-inflammatory Drugs (NSAID)
    RNAi Therapy
    Others
Segment by Application
    Hereditary Transthyretin Amyloidosis (hATTR)
    Wild Type Transthyretin Amyloidosis (wtATTR)
By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA
By Company
    Pfizer Inc
    GlaxoSmithKline Plc
    Eidos Therapeutics
    Ionis Pharmaceuticals, Inc
    Alnylam Pharmaceuticals
    Prothena Corporation Plc
    Intellia Therapeutics, Inc
    Corino Therapeutics, Inc
    Ionis Pharmaceuticals, Inc
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Transthyretin Stabilizers
1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
1.2.4 RNAi Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hereditary Transthyretin Amyloidosis (hATTR)
1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR)
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2016-2027)
2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Regions
2.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Dynamic
2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue
3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2016-2021)
3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue
3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio
3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served
3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type
4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027)
5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application
5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
6.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
6.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
6.2.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
6.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
6.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
6.3.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
6.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
6.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
7.2.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
7.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
7.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
8.2.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
8.3.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.4.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
9.2.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
9.3.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
9.4.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
10.2.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
10.3.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
10.4.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Company Details
11.1.2 Pfizer Inc Business Overview
11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.1.5 Pfizer Inc Recent Development
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Details
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.2.5 GlaxoSmithKline Plc Recent Development
11.3 Eidos Therapeutics
11.3.1 Eidos Therapeutics Company Details
11.3.2 Eidos Therapeutics Business Overview
11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.3.5 Eidos Therapeutics Recent Development
11.4 Ionis Pharmaceuticals, Inc
11.4.1 Ionis Pharmaceuticals, Inc Company Details
11.4.2 Ionis Pharmaceuticals, Inc Business Overview
11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.4.5 Ionis Pharmaceuticals, Inc Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Prothena Corporation Plc
11.6.1 Prothena Corporation Plc Company Details
11.6.2 Prothena Corporation Plc Business Overview
11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.6.5 Prothena Corporation Plc Recent Development
11.7 Intellia Therapeutics, Inc
11.7.1 Intellia Therapeutics, Inc Company Details
11.7.2 Intellia Therapeutics, Inc Business Overview
11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.7.5 Intellia Therapeutics, Inc Recent Development
11.8 Corino Therapeutics, Inc
11.8.1 Corino Therapeutics, Inc Company Details
11.8.2 Corino Therapeutics, Inc Business Overview
11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.8.5 Corino Therapeutics, Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Transthyretin Stabilizers
    Table 3. Key Players of Nonsteroidal Anti-inflammatory Drugs (NSAID)
    Table 4. Key Players of RNAi Therapy
    Table 5. Key Players of Others
    Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2016-2021)
    Table 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2022-2027)
    Table 12. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
    Table 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
    Table 14. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
    Table 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
    Table 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players (2016-2021)
    Table 18. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2020)
    Table 19. Ranking of Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
    Table 23. Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2016-2021)
    Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2016-2021)
    Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
    Table 38. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
    Table 39. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
    Table 44. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021) & (US$ Million)
    Table 50. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027) & (US$ Million)
    Table 51. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
    Table 56. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
    Table 62. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
    Table 63. Pfizer Inc Company Details
    Table 64. Pfizer Inc Business Overview
    Table 65. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 66. Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 67. Pfizer Inc Recent Development
    Table 68. GlaxoSmithKline Plc Company Details
    Table 69. GlaxoSmithKline Plc Business Overview
    Table 70. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 71. GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 72. GlaxoSmithKline Plc Recent Development
    Table 73. Eidos Therapeutics Company Details
    Table 74. Eidos Therapeutics Business Overview
    Table 75. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 76. Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 77. Eidos Therapeutics Recent Development
    Table 78. Ionis Pharmaceuticals, Inc Company Details
    Table 79. Ionis Pharmaceuticals, Inc Business Overview
    Table 80. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 81. Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 82. Ionis Pharmaceuticals, Inc Recent Development
    Table 83. Alnylam Pharmaceuticals Company Details
    Table 84. Alnylam Pharmaceuticals Business Overview
    Table 85. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 86. Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 87. Alnylam Pharmaceuticals Recent Development
    Table 88. Prothena Corporation Plc Company Details
    Table 89. Prothena Corporation Plc Business Overview
    Table 90. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 91. Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 92. Prothena Corporation Plc Recent Development
    Table 93. Intellia Therapeutics, Inc Company Details
    Table 94. Intellia Therapeutics, Inc Business Overview
    Table 95. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 96. Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 97. Intellia Therapeutics, Inc Recent Development
    Table 98. Corino Therapeutics, Inc Company Details
    Table 99. Corino Therapeutics, Inc Business Overview
    Table 100. Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 101. Corino Therapeutics, Inc Recent Development
    Table 102. Research Programs/Design for This Report
    Table 103. Key Data Information from Secondary Sources
    Table 104. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type: 2020 VS 2027
    Figure 2. Transthyretin Stabilizers Features
    Figure 3. Nonsteroidal Anti-inflammatory Drugs (NSAID) Features
    Figure 4. RNAi Therapy Features
    Figure 5. Others Features
    Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2020 VS 2027
    Figure 7. Hereditary Transthyretin Amyloidosis (hATTR) Case Studies
    Figure 8. Wild Type Transthyretin Amyloidosis (wtATTR) Case Studies
    Figure 9. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Report Years Considered
    Figure 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions: 2020 VS 2027
    Figure 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2022-2027)
    Figure 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players in 2020
    Figure 15. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
    Figure 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2016-2021)
    Figure 18. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2022-2027)
    Figure 19. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 21. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 22. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
    Figure 23. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 27. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 28. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
    Figure 29. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2016-2027)
    Figure 39. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 47. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 48. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
    Figure 49. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
    Figure 55. Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Pfizer Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 59. GlaxoSmithKline Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 60. Eidos Therapeutics Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 61. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 62. Alnylam Pharmaceuticals Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 63. Prothena Corporation Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 64. Intellia Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 65. Corino Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
    Transthyretin Stabilizers
    Nonsteroidal Anti-inflammatory Drugs (NSAID)
    RNAi Therapy
    Others
Segment by Application
    Hereditary Transthyretin Amyloidosis (hATTR)
    Wild Type Transthyretin Amyloidosis (wtATTR)
By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA
By Company
    Pfizer Inc
    GlaxoSmithKline Plc
    Eidos Therapeutics
    Ionis Pharmaceuticals, Inc
    Alnylam Pharmaceuticals
    Prothena Corporation Plc
    Intellia Therapeutics, Inc
    Corino Therapeutics, Inc
    Ionis Pharmaceuticals, Inc
Read More
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Transthyretin Stabilizers
1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
1.2.4 RNAi Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hereditary Transthyretin Amyloidosis (hATTR)
1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR)
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2016-2027)
2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Regions
2.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Dynamic
2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue
3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2016-2021)
3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue
3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio
3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served
3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type
4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027)
5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application
5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
6.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
6.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
6.2.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
6.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
6.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
6.3.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
6.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
6.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
7.2.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
7.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
7.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
8.2.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
8.3.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.4.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
9.2.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
9.3.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
9.4.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
10.2.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
10.3.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
10.4.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Company Details
11.1.2 Pfizer Inc Business Overview
11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.1.5 Pfizer Inc Recent Development
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Details
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.2.5 GlaxoSmithKline Plc Recent Development
11.3 Eidos Therapeutics
11.3.1 Eidos Therapeutics Company Details
11.3.2 Eidos Therapeutics Business Overview
11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.3.5 Eidos Therapeutics Recent Development
11.4 Ionis Pharmaceuticals, Inc
11.4.1 Ionis Pharmaceuticals, Inc Company Details
11.4.2 Ionis Pharmaceuticals, Inc Business Overview
11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.4.5 Ionis Pharmaceuticals, Inc Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Prothena Corporation Plc
11.6.1 Prothena Corporation Plc Company Details
11.6.2 Prothena Corporation Plc Business Overview
11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.6.5 Prothena Corporation Plc Recent Development
11.7 Intellia Therapeutics, Inc
11.7.1 Intellia Therapeutics, Inc Company Details
11.7.2 Intellia Therapeutics, Inc Business Overview
11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.7.5 Intellia Therapeutics, Inc Recent Development
11.8 Corino Therapeutics, Inc
11.8.1 Corino Therapeutics, Inc Company Details
11.8.2 Corino Therapeutics, Inc Business Overview
11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.8.5 Corino Therapeutics, Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Read More
List of Tables
    Table 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Transthyretin Stabilizers
    Table 3. Key Players of Nonsteroidal Anti-inflammatory Drugs (NSAID)
    Table 4. Key Players of RNAi Therapy
    Table 5. Key Players of Others
    Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2016-2021)
    Table 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2022-2027)
    Table 12. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
    Table 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
    Table 14. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
    Table 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
    Table 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players (2016-2021)
    Table 18. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2020)
    Table 19. Ranking of Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
    Table 23. Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2016-2021)
    Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2016-2021)
    Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
    Table 38. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
    Table 39. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
    Table 44. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021) & (US$ Million)
    Table 50. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027) & (US$ Million)
    Table 51. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
    Table 56. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
    Table 62. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
    Table 63. Pfizer Inc Company Details
    Table 64. Pfizer Inc Business Overview
    Table 65. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 66. Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 67. Pfizer Inc Recent Development
    Table 68. GlaxoSmithKline Plc Company Details
    Table 69. GlaxoSmithKline Plc Business Overview
    Table 70. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 71. GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 72. GlaxoSmithKline Plc Recent Development
    Table 73. Eidos Therapeutics Company Details
    Table 74. Eidos Therapeutics Business Overview
    Table 75. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 76. Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 77. Eidos Therapeutics Recent Development
    Table 78. Ionis Pharmaceuticals, Inc Company Details
    Table 79. Ionis Pharmaceuticals, Inc Business Overview
    Table 80. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 81. Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 82. Ionis Pharmaceuticals, Inc Recent Development
    Table 83. Alnylam Pharmaceuticals Company Details
    Table 84. Alnylam Pharmaceuticals Business Overview
    Table 85. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 86. Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 87. Alnylam Pharmaceuticals Recent Development
    Table 88. Prothena Corporation Plc Company Details
    Table 89. Prothena Corporation Plc Business Overview
    Table 90. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 91. Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 92. Prothena Corporation Plc Recent Development
    Table 93. Intellia Therapeutics, Inc Company Details
    Table 94. Intellia Therapeutics, Inc Business Overview
    Table 95. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 96. Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 97. Intellia Therapeutics, Inc Recent Development
    Table 98. Corino Therapeutics, Inc Company Details
    Table 99. Corino Therapeutics, Inc Business Overview
    Table 100. Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
    Table 101. Corino Therapeutics, Inc Recent Development
    Table 102. Research Programs/Design for This Report
    Table 103. Key Data Information from Secondary Sources
    Table 104. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type: 2020 VS 2027
    Figure 2. Transthyretin Stabilizers Features
    Figure 3. Nonsteroidal Anti-inflammatory Drugs (NSAID) Features
    Figure 4. RNAi Therapy Features
    Figure 5. Others Features
    Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2020 VS 2027
    Figure 7. Hereditary Transthyretin Amyloidosis (hATTR) Case Studies
    Figure 8. Wild Type Transthyretin Amyloidosis (wtATTR) Case Studies
    Figure 9. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Report Years Considered
    Figure 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions: 2020 VS 2027
    Figure 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2022-2027)
    Figure 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players in 2020
    Figure 15. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
    Figure 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2016-2021)
    Figure 18. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2022-2027)
    Figure 19. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 21. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 22. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
    Figure 23. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 27. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 28. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
    Figure 29. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2016-2027)
    Figure 39. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 47. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 48. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
    Figure 49. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
    Figure 55. Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Pfizer Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 59. GlaxoSmithKline Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 60. Eidos Therapeutics Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 61. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 62. Alnylam Pharmaceuticals Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 63. Prothena Corporation Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 64. Intellia Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 65. Corino Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3900
This license allows only one user(purchaser of the report) to access the PDF.

Multi User

Electronic (PDF)
$5850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)
$7800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Leap India

RELATED REPORTS

Global Transthyretin amyloid cardiomyopathy ATTR CM Treatment Market Size Status and Forecast 2021 2027
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-0N4529
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Neurostimulation Devices Market Research Report 2021
Global Neurostimulation Devices Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-5L4440
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Neurosurgical Products Market Research Report 2021
Global Neurosurgical Products Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-23W4063
Fri Jan 29 00:00:00 UTC 2021

Add to Cart

Global Neurosurgical Drainage Devices Market Research Report 2021
Global Neurosurgical Drainage Devices Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-9T4422
Fri Jan 29 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0